HEL Equity Snapshot
FARON Weekly Equity Report
Faron Pharmaceuticals Oy
What the company does
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response …
What the weekly tape is saying
FARON closed the latest completed week at 0.49 EUR. The 4-week return is -0.2% and the 12-week return is -1.5%. Trend Signal is inactive, Market Dynamics is 0.36. Setup signature: Risk-first tape with a 25/100 composite read.
A compressed read of the whole setup
The radar blends trend persistence, momentum, Market Dynamics, Relative Strength, volume confirmation, and risk control into one weekly cockpit.
Scoreboard
16-week signal tape
Price, Trend Line, and Fair Value
Weekly price context with the latest close, trend position, Fair Value gap, drawdown, and 52-week range location.
52-week price path
Price map
- Trend Line
- 1.13 EUR
- Vs Trend Line
- -56.5%
- Fair Value
- 2.24 EUR
- Vs Fair Value
- -78.1%
- 52W High
- 2.77 EUR
- 52W Low
- 0.44 EUR
- Drawdown
- -82.3%
- Range Position
- 2.4%
Returns and trend persistence
Return windows separate the latest week from short-term and medium-term follow-through.
Return windows
Trend read
- Active Streak
- 0 weeks
- 52W Active Weeks
- 6
- 52W Active Breadth
- 11.5%
- Sector Scope
- FI Healthcare
- Sector Rank
- 11 of 16
- Sector Percentile
- 33.3%
Sector and industry pulse
Peer breadth helps separate a stock-specific move from a broader group rotation.
FI Healthcare
- Tracked Peers
- 16
- 4W Rank
- 10 of 16
- Avg 1W
- -2.1%
- Avg 4W
- 0.7%
- Trend Breadth
- 18.8%
- Positive MD
- 50.0%
FI Biotechnology
- Tracked Peers
- 3
- 4W Rank
- 2 of 3
- Avg 1W
- -4.8%
- Avg 4W
- 0.2%
- Trend Breadth
- 0.0%
- Positive RS
- 0.0%
Pressure, Relative Strength, and expectation
Market Dynamics and Relative Strength show whether buying pressure and relative leadership are confirming the price move.
Dynamics path
Signal state
- Market Dynamics
- 0.36
- 4W MD Change
- 143.4%
- Relative Strength
- -74.64
- 4W RS Change
- 3.4%
- Expectation
- Undecided
- Probability
- 45.55%
Participation and confirmation
Volume tells us whether the latest weekly move is being confirmed by unusual participation.
52-week volume profile
Volume map
- Latest Volume
- 2.7M
- 13W Average
- 4.1M
- 52W Average
- 2.9M
- Vs 13W
- 0.7x
- Vs 52W
- 0.9x
Volatility, downside weeks, and return shape
A compact risk profile shows whether the move is steady, volatile, or being driven by sharp one-week jumps.
26-week return distribution
Risk map
- 13W Volatility
- 5.5%
- 52W Volatility
- 11.1%
- Upside Weeks
- 19
- Downside Weeks
- 33
- Downside Breadth
- 63.5%
- Avg Gain / Loss
- 5.7% / -6.7%
Classification, opportunities, risks, and watch points
Top-level read across company classification, constructive evidence, caution points, and the next things that matter.
Classification
- Exchange
- HEL
- Country
- FI
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- EUR
- Market Cap
- 116.5M
Opportunity signals
- Market Dynamics is positive on the latest completed week.
Risk signals
- Trend Signal is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- The share remains more than 20% below its 52-week high.
Watch next
- Trend Line remains the key weekly regime level.
- Market Dynamics is the pressure gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Recent completed weeks
The latest weekly rows behind the report snapshot.
| Week | Close | Return | Trend | Fair Value | MD | RS | Volume | Signal |
|---|---|---|---|---|---|---|---|---|
| 12 Jun 2026 | 0.49 EUR | -3.8% | 1.13 EUR | 2.24 EUR | 0.36 | -74.64 | 2.7M | Off |
| 5 Jun 2026 | 0.51 EUR | -4.7% | 1.18 EUR | 2.26 EUR | 0.18 | -74.93 | 2.4M | Off |
| 29 May 2026 | 0.54 EUR | 8.2% | 1.24 EUR | 2.28 EUR | -0.06 | -74.40 | 6.5M | Off |
| 22 May 2026 | 0.50 EUR | 0.6% | 1.30 EUR | 2.29 EUR | -0.49 | -77.20 | 2.1M | Off |
| 15 May 2026 | 0.49 EUR | 3.2% | 1.36 EUR | 2.31 EUR | -0.83 | -77.25 | 1.9M | Off |
| 8 May 2026 | 0.48 EUR | 0.2% | 1.41 EUR | 2.33 EUR | -0.98 | -78.40 | 3.0M | Off |
| 1 May 2026 | 0.48 EUR | 2.1% | 1.47 EUR | 2.35 EUR | -1.05 | -79.33 | 4.5M | Off |
| 24 Apr 2026 | 0.47 EUR | -7.7% | 1.52 EUR | 2.37 EUR | -1.09 | -79.92 | 3.1M | Off |
| 17 Apr 2026 | 0.51 EUR | 2.3% | 1.58 EUR | 2.39 EUR | -1.11 | -78.97 | 6.9M | Off |
| 10 Apr 2026 | 0.49 EUR | -10.4% | 1.63 EUR | 2.41 EUR | -1.15 | -79.63 | 8.0M | Off |
| 3 Apr 2026 | 0.55 EUR | 10.0% | 1.69 EUR | 2.43 EUR | -1.22 | -77.10 | 3.3M | Off |
| 27 Mar 2026 | 0.50 EUR | 0.4% | 1.74 EUR | 2.45 EUR | -1.28 | -78.87 | 3.5M | Off |
| 20 Mar 2026 | 0.50 EUR | -1.2% | 1.81 EUR | 2.47 EUR | -1.32 | -79.65 | 5.0M | Off |
| 13 Mar 2026 | 0.51 EUR | -15.1% | 1.88 EUR | 2.48 EUR | -1.34 | -80.26 | 4.4M | Off |